1990至2021年中国及全球多囊卵巢综合征与相关不孕负担趋势分析
本研究基于全球疾病负担(GBD)数据库1990至2021年数据,分析中国及全球多囊卵巢综合征(PCOS)及 attributable 不孕的年龄标化负担特征,采用Joinpoint计算平均年度百分比变化(AAPC)及95%CI,并用ARIMA模型预测2022至2036年负担。结果显示中国及全球PCOS负担持续上升,中国上升速度高于全球,预计至2036年仍呈上升趋势。
要点
- 1990至2021年中国PCOS的ASIR、ASPR和ASDR的AAPC分别为2%、2%和2.1%,均高于全球的0.8%。
- 中国PCOS相关不孕的ASPR和ASYR的AAPC分别为1.9%和2%,全球分别为1%和0.9%。
- 预测至2036年中国PCOS的ASIR、ASPR和ASDR分别达71.64/10万、1912.27/10万和16.48/10万。
核心结论
- 1990至2021年中国及全球PCOS及PCOS相关不孕负担持续上升,PCOS成为重要公共卫生问题。
- 提高公众对该常见病的认识以减少并发症已成为需关注的公共卫生优先事项。
研究设计与样本
- 基于GBD数据库1990至2021年开放数据,分析中国及全球PCOS和PCOS相关不孕的负担特征。
- 采用Joinpoint计算AAPC及95%CI,采用ARIMA模型预测2022至2036年疾病负担。
主要发现
- 1990至2021年中国PCOS的ASIR、ASPR和ASDR的AAPC分别为2%、2%和2.1%。
- 全球PCOS的ASIR、ASPR和ASDR的AAPC均为0.8%。
- 全球PCOS相关不孕的ASPR和ASYR的AAPC分别为1%和0.9%,中国分别为1.9%和2%。
- 预测至2036年中国PCOS的ASIR、ASPR和ASDR分别为71.64/10万、1912.27/10万和16.48/10万。
- 预测至2036年全球PCOS的ASIR、ASPR和ASDR分别为68.64/10万、1934.92/10万和16.91/10万。
关键数值与推荐
- 中国PCOS的ASIR、ASPR和ASDR的AAPC分别为2%、2%和2.1%,全球均为0.8%。
- 中国PCOS相关不孕的ASPR和ASYR的AAPC分别为1.9%和2%,全球分别为1%和0.9%。
- 预测2036年中国PCOS的ASIR、ASPR和ASDR分别为71.64/10万、1912.27/10万和16.48/10万。
- 预测2036年全球PCOS的ASIR、ASPR和ASDR分别为68.64/10万、1934.92/10万和16.91/10万。
- PCOS相关不孕的ASPR和ASYR预计将继续上升趋势。
临床怎么用
- 临床应关注PCOS及其相关不孕的长期管理,尤其在中国负担上升更快的背景下。
- 提高对PCOS的公众认知,以减少并发症,应作为公共卫生重点。
- 可参考GBD趋势数据优化资源配置和早期干预策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What is the global and Chinese burden of polycystic ovary syndrome (PCOS) and infertility attributable to PCOS on the basis of age-standardized calculations from 1990 to 2021? DESIGN: Using open data from the Global Burden of Disease (GBD) database from 1990 to 2021, this study analysed the characteristics of PCOS and infertility attributable to PCOS in China and worldwide. Joinpoint was used to calculate the average annual percentage change (AAPC) and the corresponding 95% CI. An autoregressive integrated moving average (ARIMA) model was used to project the burden of disease from 2022 to 2036. RESULTS: From 1990 to 2021, the AAPC of the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR) and age-standardized disability-adjusted life years rate (ASDR) of PCOS in China were 2%, 2% and 2.1%, respectively. Worldwide, the respective figures were 0.8%, 0.8% and 0.8%, respectively. The AAPC for ASPR and age-standardized years lived with disability rate (ASYR) for the global burden of infertility attributable to PCOS were 1% and 0.9%, respectively, compared with 1.9% and 2%, respectively, in China. By 2036, ASIR, ASPR and ASDR of PCOS in China are projected to increase to 71.64/100,000, 1912.27/100,000 and 16.48/100,000, respectively. Globally, these rates are projected to reach 68.64/100,000, 1934.92/100,000 and 16.91/100,000, respectively. ASPR and ASYR for infertility attributable to PCOS are predicted to continue their upward trend. CONCLUSION: From 1990 to 2021, the burden of PCOS and infertility attributable to PCOS continued to rise in China and globally, making PCOS a major public health problem. Raising public awareness of this common disease in order to reduce complications has become a public health priority that needs attention.
引用
- Liang Q. Trend analysis of the burden of PCOS and related infertility in China and worldwide between 1990 and 2021. Reprod Biomed Online. 2025. PMID: 41456540. doi:10.1016/j.rbmo.2025.105239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。